Patient P-01570
Therapy response
Stable
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
72%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 48 SC-12 recommended — Supportive Compound SC-12
- Day 49 Patient accepted — Started SC-12 in the companion
- Day 53 GI-04 recommended — GI Support Protocol GI-04
- Day 54 Patient accepted — Started GI-04 in the companion
- Day 55 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 55 GI symptom burden −25% vs expected — Supportive Compound SC-12
- Day 61 Tolerance state changed — Unstable → Improving
- Day 62 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 55.
Primary contributors, last 14 days
- Nutritional resilience-8
- Treatment adherence-8
- GI instability+6
- Inflammatory activity+4
- Toxicity+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- Supportive Compound SC-12Day 48Result: symptom burden −25%
- GI Support Protocol GI-04Day 53Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
88%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
- WearableSleep 5.7 h, below personal baseline
- Autonomic recovery ↓65
- WearableResting HR 74 bpm
- Wearable1,981 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 44
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 23/100
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 1.9 · butyrate capacity 23/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 43 ms
- Sleep
- 5.5 h
- Steps
- 2,752
- Resting HR
- 74 bpm
Daily log: GI score 50, nutritional resilience 38, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01556 | 63% | S14 | GI-04 | improved | 44 |
| P-01473 | 59% | S14 | GI-04 | improved | 51 |
| P-01339 | 58% | S14 | GI-04 | improved | 54 |
| P-01431 | 57% | S14 | GI-04 | improved | 41 |
| P-01433 | 57% | S14 | GI-04 | improved | 48 |
| P-01611 | 57% | S14 | GI-04 | improved | 44 |
| P-01365 | 56% | S14 | SC-12 | improved | 49 |
| P-01603 | 56% | S14 | GI-04 | improved | 40 |
| P-01307 | 55% | S14 | GI-04 | improved | 43 |
| P-01486 | 55% | S18 | GI-04 | improved | 47 |
| P-01496 | 55% | S14 | SC-12 | improved | 46 |
| P-01458 | 54% | S14 | GI-04 | improved | 44 |